Optimal statin type and dosage for vascular patients

Journal of Vascular Surgery

Volumn 53, Issue 3, 2011, Pages 837-844

  Paraskevas, Kosmas I ^a   Mikhailidis, Dimitri P ^b   Veith, Frank J ^c  

^a RED CROSS HOSPITAL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TROPONIN;

ABDOMINAL AORTA ANEURYSM; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY DISEASE; CONSENSUS; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; ENDOVASCULAR SURGERY; HEART INFARCTION; HUMAN; LIVER FUNCTION TEST; MEDLINE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 79951854694     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2010.10.114     Document Type: Review

References (89)

1. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:484-93.
2. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des 2007;13:3622-36. (Pubitemid 350238933)
3. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol 2008;6:237-9.
4. Paraskevas KI, Hamilton G, Mikhailidis DP. Statins: an essential component in the management of carotid artery disease. J Vasc Surg 2007;46:373-86.
5. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007;45:645-54.
6. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Are statins an option in the management of abdominal aortic aneurysms? Vasc Endovasc Surg 2008;42:128-34.
7. Paraskevas KI, Athyros VG, Briana DD, Kakafika AI, Karagiannis A, Mikhailidis DP. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets 2007;8:942-51.
8. Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in cholesterol Levels (SPARCL) trial. Stroke 2008;39:3297-302.
9. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing noncardiac vascular surgery? Eur J Vasc Endovasc Surg 2006;32:286-93.
10. Coppola G, Novo S. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. Arch Med Res 2007;38:479-88. (Pubitemid 46873814)
11. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
12. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated metaanalysis. Clin Ther 2009;31:236-44.
13. Rouleau J. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) trial. Am J Med 2005;118(Suppl 12A):28-35.
14. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Rosuvastatin Study Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51.
15. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003;91:33-41. (Pubitemid 36054166)
16. Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91:3C-10C.
17. Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for lowdensity lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-78.
18. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91:11C-7C.
19. McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:689-98. (Pubitemid 37466137)
20. Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother 2007;5:185-94.
21. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al. Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43.
22. Tomizawa A, Hattori Y, Suzuki K, Okayasu T, Kase H, Satoh H, et al. Effects of rosuvastatin on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs rosuvastatin. Int J Cardiol 2010;144:108-9.
23. Benner JS, Smith TW, Klingman D, Tierce JC, Mullins CD, Pethick N, et al. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health 2005;8:618-28. (Pubitemid 43110276)
24. Hirsch M, O'Donnell JC, Jones P. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil 2005;12:18-28. (Pubitemid 40388289)
25. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
26. Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation 2010;122:1478-87.
27. García-Rodríguez LA, González-Pérez A, Stang MR, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf 2008;17:953-61.
28. García-Rodríguez LA, Massó-González EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008;17:943-52.
29. Ferdinand KC. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. Expert Opin Pharmacother 2005;6:1897-910. (Pubitemid 41363583)
30. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 2010;10:11-28.
31. Sirtori CR, Calabresi L, Pisciotta L, Cattin L, Pauciullo P, Montagnani M, et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutr Metab Cardiovasc Dis 2005;15:47-55. (Pubitemid 40546034)
32. Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 2008;30:195-205. (Pubitemid 351834719)
33. Foody JM, Joyce AT, Jeffers BW, Liu LZ, Benner JS. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin Therapy in Hypertensive patients without Prior cardiovascular Disease. Am J Ther 2010 March 8;[Epublication ahead of print].
34. Ara R, Rafia R, Ward SE, Wierzbicki AS, Reynolds TM, Rees A, et al. Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Rev Pharmacoecon Outcomes Res 2009;9:423-33.
35. Taylor DC, Pandya A, Thompson D, Chu P, Graff J, Shepherd J, et al. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the united Kingdom, Spain, and Germany, based on the Treating to New Targets study. Eur J Health Econ 2009;10:255-65.
36. Wierzbicki AS, Mikhailidis DP. Dose-response effects of atorvastatin and simvastatin on high density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 2002;84:53-7. (Pubitemid 34718090)
37. Doggrell SA. Is atorvastatin superior to other statins? In analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Rev Recent Clin Trials 2006;1:143-53.
38. Cobos A, Jovell AJ, García-Altés A, García-Closas R, Serra-Majem L. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis. Clin Ther 1999;21:1924-36.
39. Wilson K, Marriott J, Fuller S, Lacey L, Gillen D. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. Pharmacoeconomics 2003;21(Suppl 1): 1-11. (Pubitemid 36332380)
40. Davidson MH, Palmisano J, Wilson H, Liss C, Dicklin MR. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d. Clin Ther 2003;25:2738-53. (Pubitemid 37510587)
41. Asberg A, Holdaas H. Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev Cardiovasc Ther 2004;2:641-52. (Pubitemid 39255529)
42. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and metaanalysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139-51.
43. Grines CL. The role of statins in reversing atherosclerosis: what the latest regression studies show. J Interv Cardiol 2006;19:3-9.
44. Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A. Adverse effects of statins - mechanisms and consequences. Curr. Drug Saf 2009;4:209-28.
45. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009;29:412-22.
46. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45. (Pubitemid 41627921)
47. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes; phase Z of the A to Z trial. JAMA 2004;292:1307-16.
48. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007;29:253-60. (Pubitemid 46661859)
49. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28:26-35. (Pubitemid 43254987)
50. National Cholesterol Education Program (NCEP) Expert. Panel on Detection, Evaluation, and treatment of High Blood cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
51. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010;85:349-56.
52. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92. (Pubitemid 38552793)
53. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-5. (Pubitemid 40250595)
54. Bhatia L, Byrne CD. There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk. Evid Based Med 2010;15:84-5.
55. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
56. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008;44:2122-32.
57. Statins: beware during pregnancy. Prescrire Int 2006;15:18-9.
58. LaRosa JC. Is aggressive lipid-lowering effective and safe in the older adult? Clin Cardiol 2005;28:404-7.
59. Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol 2008;17:92-100.
60. Bruckert E, Verpilleux MP, Dejager S, Isaacsohn J. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus ≥65 years of age. Am J Cardiol 2005;96:1142-8. (Pubitemid 41416610)
61. Al-Omran M, Mamdani MM, Lindsay TF, Melo M, Juurlink DN, Verma S; Systematic Assessment of Vascular Risk Investigators. Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. J Vasc Surg 2008;48:607-12.
62. Li M, Ong KL, Tse HF, Cheung BM. Utilization of lipid lowering medications among adults in the United States 1999-2006. Atherosclerosis 2010;208:456-60.
63. Steinberg BA, Braganza AJ, Eminowicz G, Dibattiste PM, Flaker GC, Murphy SA, et al. Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18. Crit Pathw Cardiol 2005;4:169-73. (Pubitemid 41697496)
64. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol 2010;8:632-7.
65. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab 2010;95:2015-22.
66. Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006;105:1260-72. (Pubitemid 44808591)
67. Schouten O, Hoeks SE, Welten GM, Davignon J, Kastelein JJ, Vidakovic R, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100:316-20. (Pubitemid 47041993)
68. Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek MR, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009;361:980-9.
69. Marshall C, Lin PH, Huynh TT, Kougias P. How optimal is the medical management of patients prior to major reconstructive vascular surgery? The results of a cross-sectional study. Vasc Endovasc Surg 2009;43:238-43.
70. nd Annual Cleveland Clinic Perioperative Medicine Summit. Cleve Clin J Med 2006;73(Electronic Suppl 1):S9-10.
71. Le Manach Y, Godet G, Coriat P, Martinon C, Bertrand M, Fleron MH, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007;104:1326-33. (Pubitemid 46795280)
72. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the statin STEMI trial. JACC Cardiovasc Interv 2010;3:332-9.
73. Hao PP, Chen YG, Wang JL, Ji WQ, Xue L, Liu XH, et al. Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease. Clin Exp Pharmacol Physiol 2010;37:496-500.
74. Smith SC, Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
75. Shiraya S, Miyake T, Aoki M, Yoshikazu F, Ohgi S, Nishimura M, et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009;202:34-40.
76. Mosorin M, Niemelä E, Heikkinen J, Lahtinen J, Tiozzo V, Satta J, et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg 2008;7:578-81.
77. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation 2008;117:1883-9. (Pubitemid 351507477)
78. Takagi H, Matsui M, Umemoto T. A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg 2010;52:1675-81.
79. McNally MM, Agle SC, Parker FM, Bogey WM, Powell CS, Stoner MC. Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. J Vasc Surg 2010;51:1390-6.
80. Spence JD, Coates V, Li H, Tamayo A, Muñoz C, Hackam DG, DiCicco M, et al. Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol 2010;67:180-6.
81. Perler BA. The effect of statin medications on perioperative and longterm outcomes following carotid endarterectomy or stenting. Semin Vasc Surg 2007;20:252-8. (Pubitemid 350245577)
82. Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP, Hamilton G. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg 2006;20:696-705. (Pubitemid 44953092)
83. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005;12:443-52. (Pubitemid 40305630)
84. Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg 2009;23:690-9.
85. Chaudhry HJ, McDermott B. Recognizing and improving patient nonadherence to statin therapy. Curr Atheroscler Rep 2008;10:19-24. (Pubitemid 351385595)
86. Casebeer L, Huber C, Bennett N, Shillman R, Abdolrasulnia M, Salinas GD, et al. Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract 2009;10:48.
87. Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Schrank W, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007;167:847-52. (Pubitemid 46658345)
88. Yilmaz MB, Biyikoglu SF, Guray Y, Karabal O, Caldir V, Cay S, et al. Level of awareness of on-treatment patients about prescribed statins. Cardiovasc Drugs Ther 2004;18:399-404. (Pubitemid 40558207)
89. RxUSA New York State Registered Pharmacy, 2010 Available at: http://rxusa.com/. Accessed October 1, 2010.